



Office de la Propriété  
Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2573800 A1 2006/03/16

(21) **2 573 800**

**(12) DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION**

**(13) A1**

(86) Date de dépôt PCT/PCT Filing Date: 2005/09/02  
(87) Date publication PCT/PCT Publication Date: 2006/03/16  
(85) Entrée phase nationale/National Entry: 2007/01/12  
(86) N° demande PCT/PCT Application No.: US 2005/031481  
(87) N° publication PCT/PCT Publication No.: 2006/029056  
(30) Priorité/Priority: 2004/09/02 (US60/606,437)

(51) Cl.Int./Int.Cl. *C07D 403/10* (2006.01)

(71) **Demandeur/Applicant:**  
TEVA PHARMACEUTICAL INDUSTRIES LTD., IL

(72) **Inventeurs/Inventors:**  
HEDVATI, LILACH, IL;  
PILARSKY, GIDEON, IL

(74) **Agent:** HEENAN BLAIKIE LLP

(54) Titre : PREPARATION D'OLMESARTAN MEDOXOMIL  
(54) Title: PREPARATION OF OLMESARTAN MEDOXOMIL

**(57) Abrégé/Abstract:**

The present invention provides a process for preparing olmesartan medoxomil.



## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
16 March 2006 (16.03.2006)

PCT

(10) International Publication Number  
WO 2006/029056 A1(51) International Patent Classification:  
C07D 403/10 (2006.01)(74) Agent: BRAINARD, Charles; Kenyon & Kenyon, One  
Broadway, New York, NY 10004-1050 (US).(21) International Application Number:  
PCT/US2005/031481(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,  
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,  
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW.(22) International Filing Date:  
2 September 2005 (02.09.2005)(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,  
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(25) Filing Language: English

## Published:

— with international search report

(26) Publication Language: English

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.(30) Priority Data:  
60/606,437 2 September 2004 (02.09.2004) US(71) Applicant (for all designated States except BB, US):  
TEVA PHARMACEUTICAL INDUSTRIES LTD.  
[IL/IL]; 5 Basel Street, P.O. Box 3190, Petah Tiqva 49131  
(IL).(71) Applicant (for BB only): TEVA PHARMACEUTICALS  
USA, INC. [US/US]; 1090 Horsham Road, P.O.Box 1090,  
North Wales, PA 19454 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HEDVATI, Lilach  
[IL/IL]; Ein-Shemer, Doar Na Hefer, 37845 Israel (IL). PI-  
LARSKY, Gideon [IL/IL]; 12/29 Ataroth, Holon, Israel  
58487 (IL).

WO 2006/029056 A1

(54) Title: PREPARATION OF OLMESARTAN MEDOXOMIL

(57) Abstract: The present invention provides a process for preparing olmesartan medoxomil.

1662/83276

## PREPARATION OF OLMESARTAN MEDOXOMIL

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/606,437 filed September 2, 2004.

5


### FIELD OF INVENTION

The present invention relates to processes for preparing olmesartan medoxomil.

### BACKGROUND OF THE INVENTION

The chemical name for olmesartan medoxomil is 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (Merck Index 13th ed.).

10 The chemical structure of olmesartan medoxomil is:




15 The empirical formula is C<sub>29</sub>H<sub>30</sub>N<sub>6</sub>O<sub>6</sub>.

The molecular weight is 558.58.


Olmesartan medoxomil is a prodrug that is hydrolyzed during absorption, and it is a selective AT<sub>1</sub> subtype angiotensin II receptor antagonist. Olmesartan medoxomil is disclosed by U.S. Patent No. 5,616,599 to Yanagisawa et al. It is marketed as BENICAR® in film-coated tablets of 5 mg, 20 mg, and 40 mg for treatment of hypertension in a human.

20 The synthesis of olmesartan medoxomil (OLM-Mod) *per se* is illustrated as follows (see also Annu. Rep. Sankyo Res. Lab 2003, 55, 1-91):




The prior art synthetic methods focus on the coupling between the substituted imidazole and the substituted biphenyl methylene bromide. Additional synthetic methods for these olmesartan medoxomil intermediates are described by: JP 11302260, JP 11292851, JP 07053489, JP 06298683, US 5621134, EP 838458, DE 19757995, US 6111114, and US 6214999.

Step (vi) (the deprotection step) of the prior art synthesis is illustrated as follows:



Example 61(b) of the '599 patent discloses a process for preparing crude olmesartan medoxomil from a mixture of trityl olmesartan medoxomil (MTT) and aqueous acetic acid.

Col. 176, lines 24-37. Triphenyl carbinol (TPC) is removed, and olmesartan medoxomil is isolated by evaporation.



Because of the acidic conditions and the presence of water, the impurity OLM-acid is  
5 also formed during the reaction by hydrolysis of the ester bond. The prior art process yields  
crude olmesartan medoxomil containing 2.2% OLM-acid per area percent HPLC.

There is a need for improved processes for preparing olmesartan medoxomil.

### **SUMMARY OF THE INVENTION**

In one aspect, the present invention provides a process for preparing olmesartan  
10 medoxomil including the steps of: contacting trityl olmesartan medoxomil with an acid in a  
water miscible organic solvent, with or without water, preferably acetone and water, to obtain  
a solution of olmesartan medoxomil and a precipitate of triphenyl carbinol; separating the  
precipitate of triphenyl carbinol from the solution of olmesartan medoxomil; and contacting  
the solution of olmesartan medoxomil with a base to obtain a precipitate of olmesartan  
15 medoxomil.

### **DETAILED DESCRIPTION OF THE INVENTION**

The present invention provides a process for preparing olmesartan medoxomil  
including the steps of: contacting trityl olmesartan medoxomil with an acid in a water  
miscible organic solvent, with or without water, to obtain a solution of olmesartan  
20 medoxomil and a precipitate of triphenyl carbinol; separating the precipitate of triphenyl  
carbinol from the solution of olmesartan medoxomil; and contacting the solution of  
olmesartan medoxomil with a base to obtain a precipitate of olmesartan medoxomil.

Preferred water miscible organic solvents include, but are not limited to, acetone,  
acetonitrile, and t-butanol. Acetone is especially preferred. Preferably, the trityl olmesartan  
25 medoxomil is contacted with a mixture of a water miscible organic solvent and water. Most  
preferably, the trityl olmesartan medoxomil is contacted with a mixture of acetone and water.  
Preferably, the ratio of water to the water miscible organic solvent, e.g., acetone, is preferably  
about 1:3 to about 3:1 by volume.

The acid that is contacted with the trityl olmesartan medoxomil removes the triphenyl  
30 carbinol to form an acid salt of olmesartan medoxomil. Preferably, the acid is a strong acid

having a pH of about 0 to about 4. Suitable acids include, but are not limited to, organic acids such as formic acid, acetic acid, benzoic acid, and oxalic acid; oxoacids such as perchloric acid, chloric acid, chlorous acid, hypochlorous acid, sulfuric acid, sulfurous acid, p-toluene sulfonic acid, nitric acid, nitrous acid, phosphoric acid, and carbonic acid; and binary acids such as hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydrocyanic acid, and hydrosulfuric acid. Hydrochloric acid, p-toluene sulfonic acid, and especially sulfuric acid are preferred. Preferably, the amount of acid is about 2 to about 8 equivalents, more preferably about 3 to about 4 equivalents, and most preferably about 3 equivalents.

When contacting the trityl olmesartan medoxomil with the acid, the temperature is preferably about 10°C to about 60°C, more preferably about 40°C. In a preferred embodiment, the combination of trityl olmesartan medoxomil, the water miscible organic solvent, and the acid is maintained for about 3 to about 15 hours. Preferably, the combination is maintained for about 4 to about 6 hours, most preferably for about 4 hours.

In a preferred embodiment, prior to separating the triphenyl carbinol, water is added to avoid the formation of undesired by-products. Preferably, the amount of added water is about 2 volumes per gram of trityl olmesartan medoxomil. Precipitation can be perceived visually as a clouding of the solution or formation of distinct particles of the precipitate suspended in the solution or collected at the bottom the vessel containing the solution.


Separating the triphenyl carbinol from the solution can be performed by any means known in the art, such as filtration or centrifugation.

After separating the triphenyl carbinol, the olmesartan medoxomil solution is contacted with a base. Suitable bases include, but are not limited to, alkali and alkaline earth metal hydroxides, carbonates, and hydrogen carbonate salts. Specific exemplary bases include, but are not limited to, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, and calcium carbonate. Potassium carbonate and especially sodium bicarbonate are preferred. Preferably, the equivalents of base used is about equal to the equivalents of acid used, that is, the amount of base used is preferably about 0.8 to 1.5 equivalents compared to the amount of acid used. The base preferably increases the pH of the solution, but the solution need not reach a basic pH. After contacting the solution with the base, the solution is preferably maintained at a temperature of about 2°C to about 25°C, preferably at about room temperature. As used herein, the term "room temperature" refers to a temperature of about 20°C to 30°C, preferably 20°C to 25°C. The solution is maintained until olmesartan medoxomil is precipitated.

The precipitate of olmesartan medoxomil can then be recovered by any means known in the art, such as filtration or centrifugation. Olmesartan medoxomil is recovered in its free base form, i.e., the nitrogen on the tetrazole is free.

The reaction progress can be detected by any method known in the art, such as, for example, HPLC, GC, TLC, NMR, and mass spectroscopy.

An exemplary embodiment of the present invention is depicted by the following scheme:



By using the process of the present invention, olmesartan medoxomil can be obtained directly, without the evaporation step required by the prior art process, which is an inconvenient industrial method. See U.S. Patent No. 5,616,599 Example 61(b). Also, the product of the '599 process is obtained in a gel-like form, which is difficult to handle in an industrial process. In addition to presenting industrial disadvantages, the '599 process achieves a lower yield than that obtained by the present invention. Additionally, the olmesartan medoxomil obtained according to the present invention has a lower amount of the impurity olmesartan acid (OLM-acid). Crude olmesartan medoxomil prepared according to the '599 process contains 2.2% OLM-acid. In contrast, crude olmesartan medoxomil prepared according the present invention contains less than about 1% OLM-acid, e.g., only about 0.89% OLM-acid. All percentages of impurities described herein are provided as area percentage HPLC at 220 nm.

## EXAMPLES

## Example 1: Preparation of olmesartan medoxomil

A 250 round bottom flask was charged with MTT (10 g), acetone/water (2/2 vol.), and 3 eq of  $H_2SO_4$ . The combination was stirred at room temperature for about 4-6 hrs.

## Example 2: Preparation of crude olmesartan medoxomil

A 1L reactor, equipped with mechanical stirrer and thermometer, was charged with MTT (70 g), acetone (140 ml), water (140 ml), and H<sub>2</sub>SO<sub>4</sub> (19.47 g). The reactor was heated to 40°C for 2.5 hrs (at EOR, MTT is LT 1%). Water (140 ml) was added at 40°C, and the reaction was stirred for 1.5 hrs or until MTT is LT 0.1%. After cooling to 15°C and stirring 5 for 1 hr, the TPC was filtered and washed with water (70 ml).

NaHCO<sub>3</sub> was added in portions to the filtrate at room temperature. The reaction mixture was stirred for 1 hr, then filtrated, and the cake was washed with water (140 ml). The solid was dried at 45°C in a vacuum oven overnight to obtain crude OLM-Mod (98 % yield).

10

Having thus described the invention with reference to particular preferred embodiments and illustrative examples, those in the art can appreciate modifications to the invention as described and illustrated that do not depart from the spirit and scope of the invention as disclosed in the specification. The examples are set forth to aid in understanding 15 the invention but are not intended to, and should not be construed to, limit its scope in any way. The examples do not include detailed descriptions of conventional methods.

**CLAIMS**

What is claimed is:

1. A process for preparing olmesartan medoxomil comprising:
  - a) contacting trityl olmesartan medoxomil with an acid in a water miscible organic solvent to obtain a solution of olmesartan medoxomil and a precipitate of triphenyl carbinol;
  - b) separating the precipitate of triphenyl carbinol from the solution of olmesartan medoxomil;
  - c) contacting the solution of olmesartan medoxomil with a base to obtain a precipitate of olmesartan medoxomil; and
  - d) recovering olmesartan medoxomil.
2. The process of claim 1, wherein the trityl olmesartan medoxomil is contacted with the water miscible organic solvent and water.
3. The process of claim 2, wherein the ratio of water to the water miscible organic solvent is about 1:3 to about 3:1 by volume.
4. The process of claim 1, wherein the water miscible organic solvent is selected from the group consisting of acetone, acetonitrile, and t-butanol.
5. The process of claim 4, wherein the water miscible organic solvent is acetone.
6. The process of claim 5, wherein the trityl olmesartan medoxomil is contacted with acetone and water, and the ratio of water to acetone is about 1:3 to about 3:1 by volume.
7. The process of claim 1, wherein the acid has a pH of about 0 to about 4.
8. The process of claim 1, wherein the acid is selected from the group consisting of sulfuric acid, hydrochloric acid, and p-toluene sulfonic acid.
9. The process of claim 8, wherein the acid is sulfuric acid.
10. The process of claim 1, wherein the amount of acid is about 2 to about 8 equivalents.
11. The process of claim 10, wherein the amount of acid is about 3 equivalents.

12. The process of claim 1, wherein step a) is performed at a temperature of about 10°C to about 60°C.
13. The process of claim 12, wherein step a) is performed at about 40°C.
14. The process of claim 1, wherein prior to step b), the solution of olmesartan medoxomil is maintained for about 3 to about 15 hours.
15. The process of claim 14, the solution of olmesartan medoxomil is maintained for about 4 to about 6 hours.
16. The process of claim 15, wherein the solution of olmesartan medoxomil is maintained for about 4 hours.
17. The process of claim 1, further comprising adding water prior to step b).
18. The process of claim 17, wherein the amount of added water is about 2 volumes per gram of trityl olmesartan medoxomil.
19. The process of claim 1, wherein the base is selected from the group consisting of potassium carbonate and sodium bicarbonate.
20. The process of claim 19, wherein the base is sodium bicarbonate.
21. The process of claim 1, wherein the amount of base used is about 0.8 to 1.5 equivalents compared to the amount of acid used.
22. The process of claim 1, wherein step c) is performed at a temperature of about 2°C to about 25°C.
23. The process of claim 22, wherein step c) is performed at about room temperature.